Name

Aurobindo Pharma USA, Inc.

Legal name

Aurobindo Pharma USA, Inc.

Website

https://aurobindousa.com

Company type

Private

Founded year

1992

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Generic APIs & Intermediates (Active Ingredients) (HLAIABAG), Specialty Pharmaceutical Distributors (HLAIAJAB), Oral Solid Dose (OSD) Generics (HLAIABAD)

Keywords

• Generic pharmaceuticals
• Active pharmaceutical ingredients
• Oral solid formulations
• Generic drug distribution
• Contract pharmaceutical manufacturing

Headquarters

HQ city

Windsor

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Generic Pharmaceutical Sales: Revenue generated from manufacturing and selling generic pharmaceuticals including oral solids, topicals, injectables, ophthalmics, and inhalations. Products are sold to national wholesalers and retail chains.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

Aurobindo Pharma USA manufactures and distributes a broad line of generic pharmaceutical products including oral solids, topicals, injectables, ophthalmics, and inhalations, supported by a vertically integrated supply chain that spans API production (17 facilities, 250+ API products), formulation, manufacturing, automated packaging, and warehousing/distribution (567,000 sq ft, 40,000 pallet capacity). The company sells exclusively through national wholesalers, retail pharmacy chains, and authorized distributors, and also markets branded specialty products such as oncology injectables through subsidiary Acrotech Biopharma and women's health products.

Product overview

Aurobindo Pharma USA is a generic pharmaceutical company offering a vertically integrated portfolio of over 225 product families including oral solids, topicals, injectables, ophthalmics, and inhalations. The portfolio spans therapeutic areas including antibiotics, antivirals, respiratory, hematology, cardiovascular, CNS, and women's health. The company operates 17 API facilities with over 250 API products on the market. Product lines include Aurovela oral contraceptives, HIV medications like Atazanavir, oncology injectables through subsidiary Acrotech Biopharma, and was developing the UB-612 COVID-19 vaccine with COVAXX. The company has approximately 60 billion dosage forms manufactured annually and serves 150 countries globally.

Differentiator

Problem solved

Functional benefit

Brands

• Aurohealth: Over the counter products division
• Auro Vaccines
• Aurobindo USA-BluePoint
• Acrotech Biopharma

Products and services

• Generic Pharmaceuticals Portfolio A broad line of AB-rated generic pharmaceutical finished dosage forms covering therapeutic categories such as antibiotics, antivirals, respiratory, hematology, cardiovascular, and central nervous system conditions, sold to national wholesalers and retail pharmacy chains.
• Active Pharmaceutical Ingredients (APIs) More than 250 active pharmaceutical ingredient products including anti-infectives, peptides, biosimilars, vaccines, and polymers, manufactured across 17 API facilities for internal formulation use and external customers.
• Aurovela Oral Contraceptives Generic oral contraceptive product line marketed as AB-rated equivalents to Loestrin products, indicated for pregnancy prevention.
• Mili and Tri-Mili Oral Contraceptives Oral contraceptive product line of AB-rated generic equivalents to Ortho Cyclen and Ortho Tri-Cyclen; Mili for pregnancy prevention and Tri-Mili additionally indicated for moderate acne vulgaris.
• Zumandimine and Lo-Zumandimine Oral Contraceptives Oral contraceptive product line of AB-rated generic equivalents to YASMIN and YAZ; Lo-Zumandimine additionally indicated for premenstrual dysphoria disorder symptoms and moderate acne.
• Atazanavir Capsules AB-rated generic equivalent of REYATAZ atazanavir capsules available in 100 mg, 150 mg, 200 mg, and 300 mg strengths, indicated in combination with other antiretrovirals for HIV treatment.
• Sildenafil Citrate Tablets AB-rated generic equivalent to VIAGRA sildenafil citrate tablets in 25 mg, 50 mg, and 100 mg strengths for the treatment of erectile dysfunction.
• Oncology Injectable Portfolio (Acrotech Biopharma) Branded specialty oncology injectable product portfolio (including Marqibo and Khapzory) held through wholly-owned subsidiary Acrotech Biopharma LLC, serving US specialty distribution channels for cancer treatment.
• UB-612 COVID-19 Vaccine Multitope peptide-based COVID-19 vaccine candidate licensed from COVAXX for development, commercialization and manufacturing for India and UNICEF markets, with initial 220 million dose capacity.
• Cephalexin For Oral Suspension USP AB-rated generic equivalent to Keflex for Oral Suspension in 125 mg/5 mL and 250 mg/5 mL strengths, indicated for respiratory tract infections, otitis media, skin/skin structure infections, bone infections, and genitourinary tract infections.
• Tofacitinib Tablets AB-rated generic equivalent to Xeljanz Tablets in 5 mg and 10 mg strengths, indicated for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
• Eluxadoline Tablets AB-rated generic equivalent to Viberzi Tablets in 75 mg and 100 mg strengths, indicated for irritable bowel syndrome with diarrhea (IBS-D).
• Canagliflozin Tablets AB-rated generic equivalent to Invokana Tablets in 100 mg and 300 mg strengths, indicated as adjunct to diet and exercise for glycemic control in adults with type 2 diabetes mellitus.
• Pirfenidone Capsules USP AB-rated generic equivalent to Esbriet Capsules in 267 mg strength, indicated for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
• Glycerol Phenylbutyrate Oral Liquid AB-rated generic equivalent to Ravicti Oral Liquid at 1.1 grams per mL, indicated as a nitrogen-binding agent for the chronic management of urea cycle disorders (UCDs).
• Dapagliflozin Tablets AB-rated generic equivalent to Farxiga Tablets in 5 mg and 10 mg strengths, indicated as adjunct to diet and exercise for glycemic control in adults with type 2 diabetes mellitus.
• Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets AB-rated generic equivalent to Xigduo XR Tablets available in four strengths, indicated as adjunct to diet and exercise for type 2 diabetes when both dapagliflozin and metformin are appropriate.
• Cefixime Capsules AB-rated generic equivalent to Suprax Capsules in 400 mg strength, indicated for urinary tract infections, pharyngitis, acute exacerbations of chronic bronchitis, and uncomplicated gonorrhea.
• Clindamycin Phosphate Gel USP AB-rated generic equivalent to Cleocin T Gel at 1% strength, indicated for the topical treatment of acne vulgaris.
• Citalopram Capsules AB-rated generic equivalent of Citalopram Capsules in 30 mg strength, indicated for the treatment of Major Depressive Disorder (MDD) in adults.
• Siponimod Tablets AB-rated generic equivalent to Mayzent Tablets in 0.25 mg, 1 mg, and 2 mg strengths, indicated for the treatment of relapsing forms of multiple sclerosis.

Quantifiable outcome

• 60 billion+ dosage forms manufactured in FY25
• +2 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Seven partnerships are on record, tiered flagship, core and minor.

• COVAXXflagshipStrategic or Co-development Partner · 24 December 2020Aurobindo Pharma entered exclusive license agreement with COVAXX to develop, commercialize and manufacture UB-612 COVID-19 vaccine for India and UNICEF. Aurobindo has capacity to manufacture 220 million doses initially with plans to expand to 480 million doses by June 2021. UB-612 is the first multitope peptide-based vaccine candidate.
• Dispensary of HopecoreGTM or Marketing PartnerAurobindo became partner to Dispensary of Hope in 2012. In 5 years, donated 3,736,413 doses of medicine. Donated products distributed to federally qualified health centers, free clinics, charitable pharmacies serving uninsured patients at or below 200% of Federal Poverty Guidelines.
• CitiHopecoreGTM or Marketing PartnerPartnership from 2013-2016 provided critically needed medicines to qualified healthcare institutions for over 333,000 patients globally, including Dominican Republic, Uganda, and Malawi. Medicines treated infectious and chronic diseases including bacterial infections, diabetes, hypertension, migraine, and depression.
• Brother's Brother FoundationcoreGTM or Marketing PartnerOngoing support of Brother's Brother Foundation for life-saving treatments. Pharmaceuticals donated to continents across 19 countries including Guatemala, Haiti, Ghana, Nigeria, Philippines, Uganda, Dominican Republic, Cameroon, Peru, Nicaragua, Honduras, Costa Rica, Malawi, Kenya, Central African Republic, India, Panama, Ecuador, and Vietnam.
• Lannett Company LLCflagshipStrategic or Co-development PartnerFTC-approved acquisition of Lannett Company LLC for $250 million cash-free, debt-free transaction. Adds Seymour, Indiana manufacturing facility with approximately 4 billion doses annual capacity. Expands portfolio in complex generics and non-opioid controlled substances. Expected to close June 2026.
• Quagen PharmaceuticalsminorOthersAs condition of FTC approval for Lannett acquisition, Aurobindo required to divest four generic pharmaceutical products to Quagen Pharmaceuticals to prevent market power consolidation in specific drug markets.
• Spectrum PharmaceuticalsflagshipStrategic or Co-development PartnerAcrotech Biopharma LLC, wholly-owned subsidiary of Aurobindo Pharma USA, acquired portfolio of seven branded oncology injectable products from Spectrum Pharmaceuticals. Transaction valued at $160 million upfront plus up to $140 million in milestones. Expected to generate $100 million revenue in first 12 months.

Scale indicators12 records

Recent moves8 records

Expansion highlights4 records

Broad incumbents

• Endo International: Specialty and generics pharmaceutical company with US-focused operations across sterile injectables, generics, and branded specialty products. Comparable in US distribution and complex generics ambitions similar to Aurobindo's Lannett integration plans.

Direct peers

• Teva Pharmaceutical Industries: The world's largest generic pharmaceutical manufacturer with an extensive US generics portfolio across oral solids, injectables, and specialty categories. Teva competes head-to-head with Aurobindo in distributing generic pharmaceuticals to US wholesalers and retail chains.
• Dr. Reddy's Laboratories: India-headquartered generics and biosimilars manufacturer with a US commercial presence. Comparable in product mix (oral solids, injectables, biosimilars), India-to-US integration, and ANDA-driven revenue model.
• Cipla: Major India-based generic pharmaceutical manufacturer with US operations and a broad portfolio of oral solids, injectables, and respiratory medications. Comparable as another vertically integrated Indian generic exporter serving the US market.
• Sun Pharmaceutical Industries: India-based global generic pharmaceutical company with a large US subsidiary (Sun Pharma Global FZE / Taro). Comparable to Aurobindo as an Indian-headquartered generic exporter with US FDA-approved manufacturing and broad US distribution through wholesalers.
• Lupin Pharmaceuticals: India-headquartered generic manufacturer with significant US presence in oral solids, injectables, and complex generics. Comparable to Aurobindo in targeting ANDA-rich therapeutic areas and supplying US national wholesalers.
• Sandoz (Novartis): Global leader in off-patent medicines, including generics and biosimilars, with a major US generics business across oral solids, injectables, and complex generics. Directly comparable to Aurobindo's vertically integrated generics model and ANDA-driven US growth strategy.
• Zydus Lifesciences: India-headquartered pharmaceutical company with US generics business and a vertically integrated API-to-finished-dose manufacturing model. Comparable in geographic origin, product mix, and ANDA-driven US growth strategy.
• Viatris (formerly Mylan): Large diversified generics and specialty manufacturer with significant US footprint across oral solids, injectables, and complex generics. Viatris's broad portfolio, ANDA pipeline, and national wholesaler relationships mirror Aurobindo's competitive position in the US market.
• Apotex: Canadian-based privately held generic pharmaceutical manufacturer with a substantial US generics business. Comparable as a privately held, vertically integrated generics competitor distributing through US wholesalers and retail chains.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/aurobindo-pharma-u-s-a-

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aurobindo Pharma USA, Inc.